Novel α- and β-amino acid inhibitors of influenza virus neuraminidase

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2563-2570

  Kati, W M ^a   Montgomery, D ^a   Maring, C ^a   Stoll, V S ^a   Giranda, V ^a   Chen, X ^a   Laver, W G ^a   Kohlbrenner, W ^a   Norbeck, D W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 2,3 DIHYDRO N ACETYLNEURAMINIC ACID; AMINO ACID DERIVATIVE; PHENYLGLYCINE; PYRROLIDINE DERIVATIVE; RIBAVIRIN; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

AMINO ACIDS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; GLYCINE; HYDROXYLATION; MODELS, MOLECULAR; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PROTEIN CONFORMATION; PYRROLIDINES;

EID: 0034878865     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2563-2570.2001     Document Type: Article

References (32)

1. Pathways for the hydrolysis of glycosides of N-acetylneuraminic acid
2. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza.neuraminidase inhibitor through structure-based drug design
3. Influenza B virus neuraminidase can synthesize its own inhibitor
4. Evidence for a sialosyl cation transition state complex in the reaction of sialidase from influenza virus
5. Hydrogen bonding and biological specificity analyzed by protein engineering
6. Transition state stabilization by deaminases: Rates of nonenzymatic hydrolysis of adenosine and cytidine
7. Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design
8. 2,3-Didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus
9. Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8-Ang. resolution: Implications for the catalytic mechanism
10. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains
11. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site
12. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors
13. Influenza virus neuraminidase with haemagglutinin activity
14. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acids
15. The behavior and significance of slow-binding enzyme inhibitors
16. Rapid colorimetric assay for cellular growth and survival: Application to proliferative and cytotoxicity assays
17. Oscillation data reduction program
18. Processing of X-ray diffraction data collected in oscillation mode
19. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase
20. Novel inhibitors of influenza sialidase related to GG167: Structure-activity, crystallographic and molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides
21. Novel inhibitors of influenza sialidase related to GG167: Synthesis of 4-amino and guanidine-4H-pyran-2-carboxylic acid-6-propylamides; selective inhibitors of influenza A virus sialidase
22. Synthesis and influenza virus sialidase inhibitory activity of the 5-desacetamido analogue of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid (GG167)
23. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071
24. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor
25. Rational design of potent sialidase-based inhibitors of influenza virus replication
26. Transition state analogues for enzyme catalysis
27. Transition state analog inhibitors and enzyme catalysis
28. Conformational aspects of inhibitor design: Enzymesubstrate interactions in the transition state
29. Transition state affinity and the design of enzyme inhibitors
30. Spontaneous hydrolysis of glycosides